Fig. 4
From: Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Personalized choice of hypoglycemic agents for patients with newly diagnosed T2D. This figure is modified according to Zhang et al.211 T2D type 2 diabetes, MASLD metabolic associated steatotic liver disease, ASCVD atherosclerotic coronary heart disease, HF heart failure, CKD chronic kidney disease, CVD cardiovascular disease, DKA diabetic ketoacidosis, Met metformin, AGI α-glucosidase inhibitors, GLP-1 glucagon-like peptide-1, SGLT-is sodium-glucose cotransporter inhibitors, DPP-4i dipeptidyl peptidase-4 inhibitors, TZD thiazolidinediones. *These regimens are considered in patients with affordability and willingness for injection therapy
